Data provided by Latvia and used for the following publication: Adverse drug reactions, particularly liver disorders, drive interruptions in anti-tuberculosis treatment: a retrospective cohort study

The cleaned data sets, code and data dictionary for EGD's Latvia chapter of her PhD. Data release can be ordered by contacting all of the following individuals: James Dear ([e-mail]); Helen Stagg ([e-mail]); Liga Kuksa ([e-mail]). Please address all data requests to all three individuals.

Publication abstract:
Data release can be ordered by the following individuals: Aim: Adverse drug reactions (ADRs) are a key driver of missed doses of anti-tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR-driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Methods: In this retrospective cohort study, adults (≥18 years) who began the standard six-month drug-sensitive anti-TB regimen in an outpatient facility in Riga, Latvia (May 2015–September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used
Results: Across 174 patients, 54 (31.0%, CI: 24.2-37.9%) missed doses due to ADRs. 4,217/31,320 (13.5%, CI: 13.1-13.9%) of doses were missed- 20.9% (880/4,217, CI: 19.6-22.1%) were due to ADRs. 18/174 (10.3%) patients discontinued treatment early, 2/18 (11.1%) due to ADRs. Doses missed due to ADRs caused longer yet less frequent periods of sporadic missed doses: 56.4% (479/849) of sporadic missed doses were one day in length versus only 9.1% (7/77) for ADR-related ones. Hepatobiliary disorders were the leading ADR group causing missed doses. Hepatobiliary ADRs caused long median durations of missed doses (median 15.0, CI: 13.0-22.0).
Conclusion: Our study underscores the importance of ADRs as a cause of missed doses of treatment, particularly hepatobiliary disorders. Regimens that are less prone to ADRs and strong healthcare system support structures for patients with ADRs are required to minimise missed doses, reducing unfavourable outcomes.